Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFOCUS: FMT in Ulcerative Colitis
NCT04968951Phase 1Terminated
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Fecal Microbiota Transplantation Capsule in ulcerative colitis (UC) (2 arms). Primary endpoints: Proportion of participants with an adverse event at 8 weeks and Proportion of participants with a severe adverse event at 8 weeks. Started Nov 2021; status: terminated.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04968951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968951.